drugset
drugset / Trial / NCT02870400

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

NCT02870400 ↗

Phase 1 Completed 41 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupTriple-blindBasic science

Summary

The primary objective of the study is to assess the safety and tolerability of single ascending doses of REGN2477 in healthy women not of childbearing potential.

Timeline

Start
2016-07
Primary completion
2017-01-12
Completion
2017-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Garetosmab Monoclonal antibody — Intravenous

Indications

No indication recorded.